Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorChildren's Hospital Medical Center, Cincinnati
The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.
Be 18 years of age or older
Be scheduled for allogeneic stem cell transplant.
Have a vitamin A level < upper limit of normal for age.
Be able to tolerate enteral vitamin dose administration.
Ongoing raised intracranial pressure
Liver cirrhosis
Patients will be excluded if they are currently pregnant.